APO RESEARCH · REPORT
GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Selected research
Industry Research
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Research Report 2026
Market perspective
The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of GLP-1 Agonists for the Treatment of both Diabetes and Obesity include Novo Nordisk and Eli Lilly, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Company
Novo Nordisk
Eli Lilly
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type
Tirzepatide
Semaglutide
Liraglutide
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application
Retail Pharmacies
Hospital and Clinic
Other
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tirzepatide
- Semaglutide
- Liraglutide
Applications
- Retail Pharmacies
- Hospital and Clinic
- Other
Companies covered
- Novo Nordisk
- Eli Lilly
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tirzepatide
- 2.2.3 Semaglutide
- 2.2.4 Liraglutide
- 2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Retail Pharmacies
- 2.3.3 Hospital and Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Type
- 3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Type (2021-2026)
- 3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (2027-2032)
4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Application
- 4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Application (2021-2026)
- 4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Perspective (2021-2032)
- 5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Growth Trends by Region
- 5.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Region (2021-2026)
- 5.2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (2027-2032)
- 5.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics
- 5.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends
- 5.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
- 5.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges
- 5.3.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue
- 6.1.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue (2021-2026)
- 6.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Players (2021-2026)
- 6.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Head Office and Area Served
- 6.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players, Product Type & Application
- 6.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Manufacturers Established Date
- 6.6 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
- 7.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 7.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
- 8.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 8.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
- 9.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 9.4 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
- 10.2 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 10.4 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
- 11.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 11.4 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novo Nordisk
- 12.1.1 Novo Nordisk Company Information
- 12.1.2 Novo Nordisk Business Overview
- 12.1.3 Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021-2026)
- 12.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
- 12.1.5 Novo Nordisk Recent Developments
- 12.2 Eli Lilly
- 12.2.1 Eli Lilly Company Information
- 12.2.2 Eli Lilly Business Overview
- 12.2.3 Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021-2026)
- 12.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
- 12.2.5 Eli Lilly Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst